<DOC>
	<DOCNO>NCT02736968</DOCNO>
	<brief_summary>This phase IIa , randomize , placebo-controlled , single-blinded superiority treatment study compare placebo daily dose 6mg auranofin adult asymptomatic amebiasis giardiasis . A sample size 68 subject enrol amebiasis ( 34 per arm ) 68 giardiasis ( 34 per arm ) ; Power base 60 subject amebiasis 60 giardiasis completing study . Primary objectives 1 ) compare proportion subject parasitological response ( detection cysts trophozoite E. histolytica microscopic exam negative antigen detection ) Day 7 E. histolytica infection 2 ) compare proportion subject parasitological response ( detection cysts trophozoite G. lamblia microscopic exam negative antigen detection ) Day 5 Giardia infection . The length study set 3.5 year ; subject participation 7 day treatment ( amebiasis ) 5 day ( giardiasis ) follow-up day 28</brief_summary>
	<brief_title>Auranofin Trial GI Protozoa</brief_title>
	<detailed_description>This phase IIa , randomize , placebo-controlled , single-blinded superiority treatment study compare placebo daily dose 6mg auranofin adult asymptomatic amebiasis giardiasis . A sample size 68 subject enrol amebiasis ( 34 per arm ) 68 giardiasis ( 34 per arm ) ; Power base 60 subject amebiasis 60 giardiasis completing study . Primary objectives 1 ) compare proportion subject parasitological response ( detection cysts trophozoite E. histolytica microscopic exam negative antigen detection ) Day 7 E. histolytica infection 2 ) compare proportion subject parasitological response ( detection cysts trophozoite G. lamblia microscopic exam negative antigen detection ) Day 5 Giardia infection . Secondary objective E. histolytica infection 1 ) compare proportion subject parasitological response ( detection cysts trophozoite E. histolytica microscopic exam negative antigen detection ) Days 3 5 , 2 ) compare rate decrease trophozoites/cyst load qPCR stool Days 3 , 5 , 7 , 3 ) compare proportion subject negative stool antigen test day 3 , 5 , 7 , 14 , 4 ) compare proportion subject sustain cure ( detection cysts trophozoite microscopic exam negative antigen detection ) 14 28 day , 5 ) compare proportion subject relapse ( strain ) re-infection ( new strain ) positive stool 14 28 day genotyping initial vs. subsequent strain . Secondary objective Giardia infection 1 ) compare proportion subject parasitological response ( detection cysts trophozoite G. lamblia microscopic exam negative antigen detection ) Day 3 , 2 ) compare rate decrease trophozoites/cyst load qPCR stool Days 3 5 , 3 ) compare proportion subject sustain cure ( detection cysts trophozoite microscopic exam negative antigen detection ) 14 28 day , 4 ) compare proportion subject relapse ( strain ) re-infection ( new strain ) positive stool 14 28 day genotyping initial vs. subsequent strain . The length study set 3.5 year ; subject participation 7 day treatment amebiasis 5 day giardiasis follow-up day 28 .</detailed_description>
	<mesh_term>Dysentery</mesh_term>
	<mesh_term>Giardiasis</mesh_term>
	<mesh_term>Dysentery , Amebic</mesh_term>
	<mesh_term>Amebiasis</mesh_term>
	<mesh_term>Auranofin</mesh_term>
	<criteria>1 . Provide write informed consent prior initiation study procedure . 2 . Able understand comply plan study procedure available study visit . 3 . Male nonpregnant female 1865 year age , inclusive . 4 . Amebiasis giardiasis identify positive TechLab antigen test , positive wet mount trichome ( confirm PCR ) , positive stool PCR E. histolytica Giardia . If subject infect E. histolytica Giardia , enrol E. histolytica study arm . Once Entamoeba study arm fully enrol , subsequent dual infect subject enrol Giardia arm . . 5 . In otherwise good health *Note : determined medical history target physical examination , indicate base medical history , evaluate acute currently ongoing chronic medical diagnosis condition would affect assessment eligibility safety subject . Existing medical diagnosis condition ( except Subject Exclusion Criteria ) must deem stable chronic medical condition . A stable chronic medical condition define change prescription medication , dose , frequency medication last 3 month ( 90 day ) health outcome specific disease consider within acceptable limit last 6 month ( 180 day ) . Any change due change health care provider , insurance company , do financial reason , long class medication , consider violation inclusion criterion . Any change prescription medication due improvement disease outcome , determine site principal investigator appropriate subinvestigator , consider violation inclusion criterion . Subjects may chronic need ( prn ) medication , opinion site principal investigator appropriate subinvestigator , pose additional risk subject safety . Topical , nasal , inhaled medication , vitamin , contraceptive permit . 6 . Vital sign ( oral temperature , pulse , blood pressure ) within normal protocoldefined range . 7 . Laboratory test ( blood urea nitrogen , creatinine , AST , ALT , white blood cell , platelet , hemoglobin ) within normal protocoldefined reference range . *Note : ( The normal range Icddr.b laboratory test include ( ) blood urea nitrogen ( BUN ) 5 24 mg/dL , inclusive , ( b ) creatinine 53 106 umol/L , inclusive , males 44 97 umol/L , inclusive , female , ( c ) AST 38 U/L less male 32 U/L less female , ( ) ALT 41.0 U/L less male 31 U/L less female , ( e ) WBC 4.0 11.0 109/L , inclusive , ( f ) platelets 150 450 109/L , inclusive , ( g ) hemoglobin 12.5 17.5 gm/dL , inclusive , males 11.5 16.5 gm/dL , inclusive , female . Subjects eligible enrollment follow laboratory value : blood urea nitrogen le 30 mg/dL , creatinine le 133 umol/L , AST ALT le 60.0 U/L , white cell count 3.5 11.0 ( 109/L ) , platelets 100 500 ( 109/L ) , hemoglobin 11.0 18.0 gm/dL ) 8 . Urinalysis great trace protein . If high protein confirm due menstruation , repeat . 9 . Women reproductive potential must negative urine pregnancy test within 72 hour start study medication . *Note : Female subject surgically sterile via tubal sterilization , bilateral oophorectomy hysterectomy postmenopausal great 1 year consider reproductive potential . 10 . Female subject participate sexual activity could lead pregnancy must agree use highly effective contraception receive auranofin 15 week . *Note : Highly effective method contraception define low failure rate ( i.e . le 1 % per year ) use consistently correctly may include , limited , abstinence intercourse , monogamous relationship vasectomize partner , male condom spermicide , diaphragm spermicide , intrauterine device , license hormonal methods.If eligible female childbearing potential use effective contraception , hormonal contraceptive supply female subject condom provide partner trial followup period 4 month total . Females effective form birth control continue study followup period 4 month total also provide condoms partner . The method compliance birth control use confirm documented study visit . 1 . Known intolerance auranofin gold compound . 2 . Pregnant breastfeed woman woman plan become pregnant breastfeed give time study within 2 month study completion . 3 . Diarrhea ( &gt; 3 loose stools/ 24 hour ) within 7 day prior start study medication . 4 . Anticipated travel 50 km study site plan next month . 5 . Current use systemic antibiotic metronidazole . 6 . Has condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol . 7 . Concurrent participation investigational protocol receipt investigational product within previous 30 day . 8 . History alcohol drug abuse within last five year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 4, 2017</verification_date>
	<keyword>Amebic</keyword>
	<keyword>Auranofin</keyword>
	<keyword>GI Protozoa</keyword>
	<keyword>Giardiasis</keyword>
	<keyword>Reprofiled</keyword>
</DOC>